Severe diarrhoea due to use of P2Y12 inhibitor ticagrelor: a rarely reported adverse event

Ticagrelor is a part of dual antiplatelet therapy (DAPT) which has proven benefits in patients with acute coronary syndrome especially in those undergoing percutaneous coronary intervention (PCI). However, like most other drugs, it can lead to undesired and adverse effects such as dyspnoea, easy bru...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2021-07, Vol.14 (7), p.e242199
Main Authors: Rashid, Khalid, Waheed, Muhammad Aamir, Rehman, Hafeez Ur, Elzouki, Abdel-Naser
Format: Article
Language:English
Subjects:
Acute Coronary Syndrome - drug therapy
Acute coronary syndromes
Aged
Angioplasty
Aspirin
Cardiac arrhythmia
Cardiology
Cardiovascular disease
Case Report
Case reports
Diarrhea
Diarrhea - chemically induced
Dyspnea
Female
Heart attacks
Hemorrhage
Hospitals
Humans
Pain
Patients
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors - adverse effects
Purinergic P2Y Receptor Antagonists - adverse effects
Ticagrelor - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ticagrelor is a part of dual antiplatelet therapy (DAPT) which has proven benefits in patients with acute coronary syndrome especially in those undergoing percutaneous coronary intervention (PCI). However, like most other drugs, it can lead to undesired and adverse effects such as dyspnoea, easy bruising and gastrointestinal bleeding. We present a case of 70-year-old woman who developed diarrhoea following initiation of DAPT comprising of aspirin and ticagrelor following PCI. After excluding more common causes, it was attributed to ticagrelor administration and completely resolved after it was replaced with another oral antiplatelet agent. On follow-up, the patient reported complete resolution of symptoms.
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr-2021-242199